CVRX vs. CLPT, QIPT, ARAY, DRTS, OBIO, TELA, DCTH, PROF, RCEL, and KRMD
Should you be buying CVRx stock or one of its competitors? The main competitors of CVRx include ClearPoint Neuro (CLPT), Quipt Home Medical (QIPT), Accuray (ARAY), Alpha Tau Medical (DRTS), Orchestra BioMed (OBIO), TELA Bio (TELA), Delcath Systems (DCTH), Profound Medical (PROF), AVITA Medical (RCEL), and KORU Medical Systems (KRMD). These companies are all part of the "surgical & medical instruments" industry.
ClearPoint Neuro (NASDAQ:CLPT) and CVRx (NASDAQ:CVRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings, dividends and community ranking.
30.1% of ClearPoint Neuro shares are held by institutional investors. Comparatively, 75.3% of CVRx shares are held by institutional investors. 6.1% of ClearPoint Neuro shares are held by insiders. Comparatively, 18.9% of CVRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
ClearPoint Neuro has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, CVRx has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500.
In the previous week, CVRx had 3 more articles in the media than ClearPoint Neuro. MarketBeat recorded 3 mentions for CVRx and 0 mentions for ClearPoint Neuro. CVRx's average media sentiment score of 0.92 beat ClearPoint Neuro's score of 0.00 indicating that ClearPoint Neuro is being referred to more favorably in the media.
ClearPoint Neuro has a net margin of -78.84% compared to ClearPoint Neuro's net margin of -123.58%. ClearPoint Neuro's return on equity of -66.05% beat CVRx's return on equity.
ClearPoint Neuro has higher earnings, but lower revenue than CVRx. ClearPoint Neuro is trading at a lower price-to-earnings ratio than CVRx, indicating that it is currently the more affordable of the two stocks.
ClearPoint Neuro presently has a consensus price target of $12.00, suggesting a potential upside of 93.55%. CVRx has a consensus price target of $16.60, suggesting a potential upside of 100.24%. Given ClearPoint Neuro's higher probable upside, analysts clearly believe CVRx is more favorable than ClearPoint Neuro.
ClearPoint Neuro received 4 more outperform votes than CVRx when rated by MarketBeat users. Likewise, 86.96% of users gave ClearPoint Neuro an outperform vote while only 57.14% of users gave CVRx an outperform vote.
Summary
ClearPoint Neuro and CVRx tied by winning 9 of the 18 factors compared between the two stocks.
Get CVRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for CVRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CVRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
